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Effects of glucose on matrix metalloproteinase and plasmin activ- also shown accumulation of various matrix components
ities in mesangial cells: Possible role in diabetic nephropathy. [4–6]. Together, these studies support a role for HG
Diabetic nephropathy is characterized by an accumulation concentration in extracellular matrix accumulation.of mesangium matrix that correlates well with the loss of kidney
The amount and composition of mesangium matrixfunction. High glucose concentration is known to increase the
depends on a delicate balance between synthetic andsynthesis of many matrix components. Recently, we have shown
that degradation of matrix also decreases in diabetes. The ma- degradative pathways. The effects of diabetes on the
jor enzymes responsible for matrix degradation are the matrix synthetic arm of this process have been more thoroughly
metalloproteinases. The physiology of these enzymes is com- studied; HG concentration increases gene expressionplex and their activity is tightly regulated at many levels. At
and protein levels of various mesangium matrix compo-the transcriptional level matrix metalloproteinase (MMP) ex-
nents. More specifically in diabetes, an increase occurspression is increased by protein kinase C (PKC) agonists, and
some growth factors. In contrast transforming growth factor in the synthesis of collagen IV, fibronectin, and laminin
(TGF)-b can decrease MMP expression. Once synthesized, in the glomeruli although the synthesis of heparan sulfate
MMPs are secreted as inactive pro-enzymes that are activated proteoglycan is decreased [7–9]. These changes haveby other MMPs or plasmin. To effect this, plasmin must be
been replicated in vitro when mesangial cells were ex-liberated from plasminogen in the pericellular environment.
posed to HG concentrations [4–10]. How HG concentra-In turn, activated MMPs can be inhibited by binding to specific
inhibitors known as tissue inhibitor of metalloproteinases tion mediates these changes is not fully understood but
(TIMP). Cell culture and animal studies have shown that high may involve a number of cellular responses known to
glucose (HG) decreases expression of MMPs and increases regulate extracellular matrix synthesis. For example, HGexpression of TIMPs. HG can also affect MMP activation by
concentration increases protein kinase C (PKC) activity,decreasing plasmin availability and reducing expression of a
transforming growth factor-b (TGF-b) expression, mito-membrane-bound MMP called MT1-MMP. How HG induces
these changes remains to be fully elucidated. One possibility gen-activated protein (MAP) kinase activity, advanced
is that HG can increase TGF-b, which may in turn alter MMP glycation end product (AGE) accumulation, and polyol
promoter activity; this area is currently being studied in our pathway flux [11–16].laboratory.
More recently, attention has focused on the degrada-
tive arm of mesangium matrix turnover, and evidence is
increasing that HG concentration can indeed affect ma-Diabetic nephropathy, which accounts for much of the
trix degradation. There are four classes of enzymes thatmorbidity and mortality of diabetes, is characterized by
could be involved in mesangium degradation: (1) theaccumulation of mesangium matrix and thickening of
aspartic, (2) cysteine, (3) serine, and (4) metalloprotei-glomerular basement membrane. These changes in kid-
nases. Although each class is capable of degrading matrixney structure have been shown to correlate well with the
proteins, studies using specific protease inhibitors haveloss of renal function [1–3]. In vitro studies of mesangial
shown that two are primarily responsible [17–19]. Thecells cultured in high glucose (HG) concentrations have
first involves the matrix metalloproteinases (MMPs),
which comprise a large family of metal ion-dependent
neutral proteinases. They have distinct substrate speci-Key words: matrix metalloproteinase, plasmin, transforming growth
factor-b, diabetic nephropathy, matrix degradation. ficities, but when acting together can degrade almost
all matrix components. The second involves plasmin, aÓ 2000 by the International Society of Nephrology
S-81
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Table 1. The major types of MMPs found in mesangial cells
Type of MMP Alternative name Substrate
Interstitial collagenases MMP-1, MMP-8 and MMP-13 Type I, II and III collagen
Type IV collagenases/gelatinases MMP-2 and MMP-9 Type IV, V and VI collagen, fibronectin and gelatin
Stromelysins MMP-3, MMP-7 and MMP-10 Proteoglycans, laminin, fibronectin and type III, IV, V collagen
Membrane-type metalloproteinases MT1-MMP MMP-2
serine proteinase, which can degrade matrix directly but
also indirectly by converting inactive MMPs to their ac-
tive forms. Both MMPs and plasmin have been impli-
cated in the abnormal degradation of mesangium matrix
by mesangial cells in diabetes [17, 18].
Physiology of the MMPs is complex and their activities
are tightly regulated at several levels. These include gene
expression, extracellular activation, and inhibition by
specific inhibitors. MMPs are expressed in most tissues
at low levels but can be modulated by PKC agonists,
cytokines, hormones, and growth factors such as TGF-b
[20–23]. Of major interest in diabetic nephropathy is the
role of TGF-b in mesangium degradation. MMPs are
activated by cleavage of the N-terminal domain by other
MMPs or by plasmin. MMPs are inhibited by tissue inhib-
itors of MMPs (TIMPs), which bind with high affinity to
the MMP. In this paper, we briefly review the pathophys-
iology of these proteinases in relation to diabetic ne-
phropathy.
Fig. 1. Schematic diagram showing possible effects of HG concentra-MATRIX METALLOPROTEINASES IN
tion on the regulation of MMP activities.DIABETIC NEPHROPATHY
MMPs play an important role in various biologic pro-
cesses in which tissue remodeling is required, such as
as inactive proenzymes and require activation, and theywound healing, bone resorption, and trophoblast implan-
are inhibited by TIMPs. Conversely, MMPs differ fromtation. Excess production alone or combined with activa-
each other by the presence or absence of additional do-tion of MMPs is associated with various degenerative
mains that determine their substrate specificity, bindingand inflammatory diseases. In tumor invasion, expres-
to inhibitor, and matrix and cell surface localization.sion and activities of the MMPs are also increased
For example, the gelatinases (MMP-2 and MMP-9) are[24, 25]. In addition to diabetic nephropathy, MMPs can
characterized by the presence of a fibronectin-like gelatinpotentially contribute to other microvascular and macro-
binding domain found within the catalytic region. Forvascular complications of diabetes. For example, in-
other MMPs, the hemopexin domain on the C terminuscreased expression of MMPs is found within atheroscle-
confers substrate specificity. In addition, the membrane-rotic plaques and may be responsible for plaque rupture
type MMPs (MT-MMPs) contain a short transmembrane[26, 27]. Alterations in the pattern and expression of
domain, responsible for the localization of these MMPsMMPs is thought to contribute to the poor wound heal-
to the cell surface.ing often observed in patients with diabetes [28].
As discussed previously, MMP activities are tightlyThe MMPs are a family of at least 20 distinct but
controlled at the level of gene transcription and in therelated enzymes, which can be divided into four main
activation and inhibition of their biologic activity. Howsubgroups on the basis of their substrate specificity.
HG concentration can alter these are discussed later inMMPs relevant to diabetic nephropathy and their sub-
this paper and shown schematically in Fig. 1.strates are shown in Table 1. Despite the large number
of MMPs they show a great deal of structural homology
Transcriptionand share several common features: they are capable of
MMP expression can be regulated by various factorsdegrading at least one component of the extracellular
matrix, they require Zn21 to be active, they are produced including TGF-b, cytokines, regulators of the PKC path-
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way such as angiotensin II and phorbol esters, and inter- cell types of various tumors and the expression of which
is associated with increased activation of MMP-2 [45–49].actions with other cells or adjoining matrix [20–23]. Be-
cause glucose is known to increase PKC activity, increase More recent studies have shown that MT1-MMP is also
expressed by vascular endothelial cells and by mesangialthe expression of TGF-b, and change matrix composi-
tion, these are all potential mechanisms capable of modi- cells [46, 50]. In these cells, addition of concanavalin A
stimulates MT1-MMP expression and increases the acti-fying MMP expression in diabetes.
The ability of PKC and TGF-b to affect gene expres- vation of MMP-2, further supporting a role for MT1-
MMP in MMP-2 activation [47–50]. Physiologic regula-sion of MMPs partially results from changes in the pro-
duction of the proto-oncogene products c-Fos and c-Jun tors of MT1-MMP expression have not been fully charac-
terized but Lohi et al have shown that its expression can[29]. These transcription factors combine to form a com-
plex known as an activator-binding protein-1 (AP-1), be increased by the addition of phorbol esters and growth
factors [50]. Inasmuch as HG concentration can increasewhich recognizes a specific DNA that is present in the
promoter region of many MMP genes. Addition of phor- TGF-b and PKC activity, it may affect MT1-MMP ex-
pression by these mechanisms, and secondarily contrib-bol esters, cytokines, and growth factors such as platelet-
derived (PD) GF have been shown to up-regulate expres- ute to the alterations in MMP activities observed in dia-
betes. HG concentration can also increase collagension of these MMPs through this step [30–33]. However,
the effects of these AP-1 proteins on gene expression deposition and collagen has been shown to affect MT1-
MMP expression [51]. Thus, some effects of HG on mes-are complex and some types can repress gene expression.
Interestingly, the promoter of the gelatinase MMP-2 angium matrix may indirectly alter MT-MMP activities.
does not contain an AP-1 site, suggesting that its tran-
Inhibitionscription may be regulated differently [34]. Also unlike
the other MMPs, its proenzyme activation depends on Having been activated, the ability of the MMPs to
degrade mesangium matrix is further modulated byMT-MMP (see next section). In addition to AP-1 sites,
the promoters of the MMP genes contain other transacti- TIMPs that bind to the active enzyme with high affinity.
vation sites [32, 33, 35–39]. These include binding sites Four TIMPs (TIMP-1 through TIMP-4) have been iden-
for polyomavirus enhancer a-binding protein-3 (PEA-3), tified. each of which has the ability to bind and inhibit
specificity protein-1 (SP-1), nuclear factor-kappa B MMPs to some extent. Some specificity for MMP/TIMP
(NF-kB) and activator binding protein-2 (AP-2). The interactions is suggested by the observation that TIMP-1
variation in the number, combination, and spatial ar- forms a complex with proMMP-9, whereas TIMP-2 forms
rangement of these binding sites contributes to the differ- a complex with proMMP-2 [21–23]. In addition, TIMP-1
ential regulation of MMP genes and may explain their is a poor inhibitor of MT-MMP. TIMP expression can
variable responses in diabetes. As discussed more fully also be regulated by growth factors, in particular TGF-b
later in this paper, TGF-b can increase or decrease ex- [52, 53]. In some cases, these agents have opposing effects
pression of different MMP genes. Some of these oppos- on TIMP and MMP expression. For example, TGF-b
ing actions of TGF-b may be explained by its effects can induce TIMP expression and inhibit MMP expres-
on the TGF-b inhibitory element (TIE) found in the sion [52]. The relative levels of MMPs and TIMPs are
promoter region of some MMP genes [39–41]. important in the maintenance of normal matrix composi-
tion and an imbalance in their expression and activities
Activation may contribute to the accumulation of mesangium ma-
MMPs are secreted in latent forms that are incapable trix observed in diabetic nephropathy.
of effecting proteolysis. Their activation is achieved by
cleavage of the linkage between the cysteine in the pro-
ROLES OF TGF-b IN REGULATION OF MMPenzyme domain and Zn21 in the catalytic site. This results
AND TIMP EXPRESSIONin removal of the propeptide domain, thereby exposing
TGF-b is distributed ubiquitously. Active TGF-b is athe zinc atom. For most MMPs (except MMP-2), activa-
homodimer with a molecular weight of 25 kDa and threetion is achieved by the actions of plasmin or the stromely-
mammalian isoforms with similar biologic actions havesins (in particular MMP-3). Plasmin activity is decreased
been described. In this article we have used the genericin diabetes and in mesangial cells exposed to HG concen-
term TGF-b but in diabetic nephropathy, the TGF-b1tration, which retards the activation of MMPs and con-
isoform is up-regulated.tributes to decreased matrix degradation [17, 42, 43].
TGF-b is normally synthesized in a latent form in whichMMP-2 is unlike other MMPs in that it is not activated
active TGF-b is bound to a latency-associated proteinby plasmin. Instead, it is activated on the cell surface by
(LAP), the removal of which is required to unmask TGF-bMT-MMPs. To date, four MT-MMPs have been identi-
activity. The LAP-TGF-b complex can in turn be boundfied and cloned from cDNA libraries [44–47]. The best
studied is MT1-MMP, which is expressed by fibroblastic to an even larger protein known as latent TGF-b binding
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Table 2. Evidence supporting the importance of TGF-b in the EFFECTS OF HG CONCENTRATION ON
pathogenesis of diabetic nephropathy
MESANGIAL CELL MMP ACTIVITIES
• TGF-b level is increased in the kidney, blood and urine of diabetic Mesangial cells express various MMPs and TIMPs.patients and animals [57, 58]
From the previous discussion, it is clear that any effects• TGF-b expression is increased in mesangial cells exposed to HG
[57, 58] of HG concentration result from several complex inter-
• TGF-b added to cultured mesangial cells produces similar changes actions. Experiments in our laboratory and by othersin matrix components to those in the diabetic kidney [6, 12, 57, 58]
using reverse transcription polymerase chain reaction• TGF-b affects expression of MMPs and TIMPs in a pattern similar
to that observed in diabetic nephropathy [6, 12, 54, 57, 58] (RT-PCR) have shown that in the presence of HG con-
• TGF-b antibodies or antisense constructs reduce the ability of HG centration the expression of MMPs by mesangial cells isto increase matrix components in kidney and cultured mesangial
altered [18, 66–73]. Because of the complexity of theircells [6, 12, 60]
regulation, it is not surprising that the expression of
the various MMPs does not always change in the same
direction. For example, in our studies and those of Wa-
protein (LTBP), which anchors the complex to the ex- hab and Mason, culture of human mesangial cells in HG
tracellular matrix. Active TGF-b can be bound by hy- concentration increases expression of MMP-2, whereas
drophobic interactions with many extracellular matrix
expression of MMP-9 and MMP-7 decreases [18, 67].
components, including collagen IV, fibronectin and the
Adding a further level of complexity, HG concentrationproteoglycans, betaglycan, and decorin. By these mecha-
also increases the expression of TIMP-1 [66–73].nisms, TGF-b is stored in the extracellular matrix where
Unlike other MMPs, gelatinase MMP-2 is activatedit can be released for biologic actions [53–55].
on the cell surface by the actions of MT-MMPs [46–52].Evidence is abundant that increased TGF-b is a critical
Lohi et al have shown that the expression of this enzymecomponent in the pathogenesis of diabetic nephropathy
can be altered by the addition of growth factors and by[54–64]. The evidence supporting this notion is presented
PKC agonists [50]. Our own studies have shown that HGin several reviews and summarized in Table 2. TGF-b
concentration decreases expression of MT1-MMP and inplays major roles in the modulation of cell proliferation
a dose-dependent manner decreases activation of MMP-2.and in the regulation of extracellular matrix turnover.
Thus far, we have considered the interaction of glucoseIn the extracellular matrix, its predominant effects are
and cells as an independent event. Instead, expressionto increase matrix synthesis and decrease its degradation
of MMPs and TIMPs can also be regulated by cell-cell[6, 12, 57–61]. Important in the context of this article,
and cell–matrix interactions. For these reasons, it is im-TGF-b can regulate the synthesis of MMPs and TIMPs
portant to study MMP expression and activity in tissuein mesangial cells and can directly affect the expression
of many extracellular matrix components. samples obtained from animals or humans with diabetes.
The molecular mechanism of how TGF-b modulates Kitamura et al, using a mouse model of type 1 diabetes,
these effects remains to be elucidated. As indicated pre- found a decrease in the expression of MMPs, in particular
viously, the promoter regions of several MMP genes MMP-1, MMP-9, and MMP-3 [69]. Using RT-PCR, we
contain a TGF-b inhibitory element (TIE) and the gene have also shown a decrease in the expression of some
expression of these MMPs is decreased when TGF-b is MMPs in glomeruli obtained from streptozocin diabetic
added to the culture media [40]. However, the promoter rats. Similar to mesangial cells exposed to HG concentra-
regions of some MMPs do not contain a TIE (e.g., MMP-9 tion, in these glomeruli, gene expression of MMP-2 was
and MMP-3) and their expression can also be decreased increased. However, some conflicting findings exist in
by TGF-b. In these cases, TGF-b is thought to mediate the literature in this regard. Glomeruli obtained from
its effects through its actions on AP-1 [42]. As previously patients with type 2 diabetes have been shown to have
mentioned, AP-1 is a heterodimer of the Fos and Jun decreased expression of MMP-2 [70]. A similar down-
family of proteins and can occur in several different
regulation of MMP-2 expression has also been observedcombinations, the major forms being c-fos/c-jun, c-fos/
in mesangial cells obtained from diabetic NOD miceJunD, and c-fos/JunB. The first two of these induce gene
[71]. Despite these apparent discrepancies in the patterntranscription whereas the latter, that is, the JunB con-
of expression of MMP-2 in diabetes, most in vivo studiestaining AP-1, can repress gene transcription [62]. Thus,
have shown that HG concentration decreases expressionTGF-b can directly through TIE, or indirectly through
of some MMPs and increases the expression of TIMPs.AP-1, affect expression of most MMP genes. The excep-
Such changes would contribute to the decrease in thetion is MMP-2, which does not contain either an AP-1
degradation of mesangial matrix observed in diabeticsite or a TIE in its promoter region and is not regulated
nephropathy.by TGF-b. TGF-b has been shown in several studies to
The overall functional effects of HG on matrix degra-increase the expression of TIMP-1 [63–66]. By these
dation has been difficult to study, partly because of thecombined effects on MMP and TIMP expression, TGF-b
could have profound effects on matrix degradation. lack of a suitable model in which the process of degrada-
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tion can be assessed separately from synthesis. In our is thought to be involved in proteolysis during cell migra-
tion and tissue remodeling in processes such as angiogen-laboratory, we have overcome this problem by using a
biosynthetically labeled matrix as a substrate for measur- esis and atherosclerosis [79, 80]. The components of the
plasminogen cascade and their receptors have beening the rate of mesangium degradation [18]. Using this
system, we have shown that HG concentration decreases shown to be present on the cell surface and in the pericel-
lular environment of mesangial cells [42, 43]. In addition,the ability of mesangial cells to degrade matrix by two
distinct processes. the enzyme kinetics for the conversion of tissue bound
plasminogen to plasmin by t-PA or u-PA is more favor-First, HG concentration directly affects the expression
and activities of proteolytic enzymes secreted by mesan- able in comparison with the fluid state [78]. These consid-
erations suggest the importance of the pericellular plas-gial cells. Using the system described above we have
shown that culture of mesangial cells in a HG milieu minogen cascade in tissue remodeling. Thus, alterations
to components of this cascade may have profound effectsdecreases their ability to degrade normal matrix [18].
Second, HG concentration can change the matrix itself on mesangium degradation and contribute to diabetic
nephropathy.so that it becomes more resistant to degradation [18].
Although the mechanism for this phenomenon has not Using transgenic mice deficient in u-PA, Carmeliet
and Collen have shown that the u-PA/plasmin system isbeen completely explained, HG concentration is known
to alter the composition of mesangium matrix, which a significant activator of most pro-MMPs [80]. MMP-2
is the exception to this because it is activated on thein turn affects intracellular signaling pathways affecting
matrix degradation. For example, growth of cells on dif- cell surface by MT-MMPs. However, the MT-MMPs are
similar to other MMPs in that they also require activationferent extracellular matrix components can change the
pattern of MMP and TIMP expression [73]. In addition, and plasmin has been shown to be capable of this func-
tion. Therefore, plasmin still has an indirect role in theHG concentration can increase the cross-linking of colla-
gen molecules, making them less susceptible to degrada- activation of MMP-2. Plasmin can also activate and liber-
ate growth factors such as TGF-b from the extracellulartion by proteolytic enzymes [74]. This increase in cross-
linking is mediated by an accumulation of AGEs proteins, matrix [81, 82]. These direct and indirect actions of plas-
min suggest that plasmin generated in the pericellularwhich can also affect MMP expression and activities [75].
Although evidence is abundant that supports the im- environment of mesangial cells is well placed to modulate
mesangium degradation.portance of impaired mesangium degradation in the gen-
esis of diabetic nephropathy, it is extremely difficult to
locate the defective steps. MMPs have overlapping sub- EFFECT OF HG CONCENTRATION ON THE
strate specificity; MMPs often have divergent responses; MESANGIAL CELL PLASMINOGEN CASCADE
MMP activities are dependent on the plasminogen sys-
The matrix binding of plasminogen (and plasmin) istem, which is itself affected by a HG milieu; TIMP activi-
largely mediated through lysine binding sites situated inties are altered simultaneously. These factors make it
the Kringle regions of the molecule [81]. This is particu-difficult to pinpoint the exact defect(s) that may only be
larly important in diabetes in which in the presence ofidentified by experiments using knockout or overexpres-
excessive hyperglycemia, glucose binds to lysine formingsion of components of the various pathways.
initially a Schiff base, which is then progressively trans-
formed to AGEs. Because both plasminogen and glucose
PLASMINOGEN/PLASMIN CASCADE IN can bind to matrix proteins, glucose may competitively
MESANGIAL CELLS displace plasminogen from the matrix and by this mecha-
nism decrease matrix degradation. Our experiments us-In the context of mesangium turnover, the plasmino-
gen/plasmin cascade plays important roles through its ing a mesangial cell culture system showed that in the
presence of 30 mol/L glucose the incorporation of 125Iability to degrade some matrix components directly and
by its role in the activation of MMPs. plasminogen into the mesangium matrix during synthesis
was reduced when compared with control cells [41]. InThe inactive precursor, plasminogen, can be converted
to plasmin in a process stimulated by either of two PAs, addition, when the mesangium matrix was depleted of
plasminogen, it was 53% less degradable, confirming thattissue type PA (t-PA), or urokinase type PA (u-PA). This
process is modulated by PA inhibitors 1 and 2 (PAI-1 and displacement of plasminogen from the matrix by glucose
plays an important role in the decreased degradation ofPAI-2) and by a2 antiplasmin. Thus, t-PA is primarily
involved in clot dissolution although other roles have matrix in diabetic nephropathy.
In diabetes, circulating levels of PAI are elevated [82].been described [76–80]. Cellular receptors for t-PA and
plasminogen have been identified on the surface on many In accord with these in vivo data, growth of mesangial
cells in a HG environment also increases secretion ofcell types, where they localize proteolysis to the cell sur-
face. A urokinase receptor has also been described and PAI [68]. In addition, studies in this laboratory have
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